Introduction
TNM stage remains the gold standard for informing patient prognosis and guiding management after resection for non-metastatic colorectal cancer (CRC). Despite the same disease stage, however, CRC patients exhibit considerable variability in clinical outcome that is likely related to molecular tumor heterogeneity. Therefore, the molecular classification of CRC may identify patient subgroups at varying risk of recurrence and death and for who personalized approaches to therapy may beneficial. The majority of CRCs develop via the chromosomal instability pathway (CIN), whereas 12-15 % arise from the microsatellite instability (MSI) pathway that is a consequence of deficient (d) DNA mismatch repair (MMR). Deficient MMR can develop from an inherited germline mutation in a MMR gene (MLH1, MSH2, MSH6, PMS2), i.e., Lynch syndrome, or more commonly due to epigenetic inactivation of the MLH1 gene and the CpG island methylator phenotype (CIMP). These sporadic dMMR tumors carry somatic mutations in the BRAF oncogene in approximately half of cases. Studies have shown that dMMR tumors have phenotypic features including poor differentiation, proximal colon location, and abundant tumorinfiltrating lymphocytes. Furthermore, dMMR tumors have been consistently associated with a better stage-adjusted survival compared to proficient MMR (pMMR) tumors.
Among early-stage CRCs, the survival advantage of dMMR status appears to be greater among stage II compared to stage III patients. In patients with stage II colon cancers and dMMR, studies demonstrate a lack of benefit of adjuvant 5-fluorouracil (FU)-based chemotherapy. Among patients with stage III disease, the predictive impact of MMR status for adjuvant chemotherapy remains controversial. Multiple prior studies have demonstrated a lack of benefit for 5-FU as adjuvant chemotherapy, although only limited data exist for patients with stage III dMMR CRCs treated with standard the adjuvant FOLFOX regimen. In contrast to 5-FU, in vitro data indicate that dMMR/MSI CRC cell lines display sensitivity to oxaliplatin and accordingly; this agent may provide benefit in patients with dMMR CRCs.
DNA mismatch repair and microsatellite instability
The Cancer Genome Atlas (TCGA) Research Network has revealed a comprehensive characterization of the genomes of 224 cancerous colorectal tumors and normal pairs [1••] . Among CRCs studied, 16 % were found to be hypermutated, and 77 % of these tumors displayed high-frequency microsatellite instability (MSI-H) that was generally associated with hypermethylation and MLH1 gene. The remaining hypermutated tumors were primarily characterized by having mutations in somatic MMR pathways and in polymerase epsilon (POLE) [1] .
The DNA MMR system repairs base-base mispairs introduced into microsatellites during DNA synthesis to maintain genomic stability [2] . Microsatellites are short, tandemly repeated sequences that occur throughout the genome and are used as markers of deficient (d) MMR. The DNA MMR system is composed of four MMR genes and their encoded proteins (MLH1, MSH2, MSH6, PMS2). Inactivation of MLH1 and MSH2 account for over 90 % of dMMR cases. Deficiency of MMR results in production of a truncated, nonfunctional protein or loss of a protein that causes MSI. Therefore, dMMR is frequently analyzed by testing for loss of an MMR protein or for MSI using a PCR-based assay.
MSI testing
MSI testing can be performed on fresh, frozen, or paraffin-embedded tumor tissue using a PCR-based assay for detection of instability [3, 4] .
& The National Cancer Institute Workshop agreed on five microsatellite markers necessary to determine MSI [5] that include two mononucleotides-BAT25/26-and three dinucleotide markers-D2S123, D5S346, and D17S250. Interpretation of the profiles requires a comparison with normal DNA from each patient. An alternative molecular method based exclusively on quasimonomorphic mononucleotide markers was developed to avoid the analysis of matching normal DNA. This method has been proven to be more specific and sensitive than the original NCI panel [5] . & On the basis of the MSI status, CRCs can be classified into three groups:
MSI-H, if two or more of the five microsatellite markers show instability; MSI-L (low-frequency MSI), if only one of five markers shows instability; and microsatellite stable (MSS) if none of the markers show instability [6] .
MMR protein expression: immunohistochemistry
& Analysis of MMR protein expression by immunohistochemistry (IHC) is an alternative test that is widely available with the advantage of not requiring a molecular laboratory and the ability to identify the affected gene by detecting loss of its protein product. & Another advantage of IHC testing is that loss of a specific mismatch gene product (MLH1, MSH2, MSH6, and PMS2) can direct germline testing to that specific gene, and assists in the identification of patients with Lynch syndrome (LS) [4] . & MSI testing and IHC are complimentary, and loss of MMR protein expression by IHC has been shown to be highly concordant with DNAbased MSI testing with a good sensitivity (990 %) and a excellent specificity (100 %) [4] . & Only loss of hMLH1 protein expression has been described in sporadic CRCs [7] . MLH1 and PMS2 proteins are often lost together, which indicates loss of MLH1 function generally due to epigenetic silencing or germline mutation. Isolated loss of PMS2 protein generally indicates an underlying germline PMS2 mutation. & In CRCs with loss of MLH1 protein expression, testing for a mutation in the BRAF oncogene is the most cost-effective approach to confirm a sporadic case and generally exclude LS which support the use of this strategy for LS screening [8] . Patients with non-mutated BRAF would then have germline testing for a mutation in the presumed altered MLH1 gene (Fig. 1) . & MSH2 and MSH6 proteins are often lost concurrently. Isolated loss of MSH2 or MSH6 proteins on IHC testing has high specificity for a germline mutation of these genes leading to the diagnosis of LS (Fig. 1) . Also, loss of the MSH2 protein can be caused by germline mutation in the EPCAM gene rather than MSH2 gene. & Tumors displaying loss of an MMR protein can be collectively referred to as dMMR and are considered to be MSI-H, whereas those with intact MMR proteins can be classified as pMMR are expected to be microsatellite stable (MSS) or MSI-low (MSI-L).
Lynch syndrome
& LS accounts for approximately 3-4 % of all CRCs and one third of all dMMR/MSI-associated CRCs. LS is inherited in an autosomal dominant manner and results from a germline loss-of-function mutation [9] that occurs more commonly in MLH1 or MSH2 and infrequently in MSH6 or PMS2 [10] . A germline mutation in an MMR gene followed by a second hit (somatic event) to the wild-type copy is needed to produce LS and can occur due to point mutation, loss of heterozygosity, or methylation. & Patients with LS develop early age at onset of CRCs, and rates of synchronous CRCs increase with age. & Patients with LS are at highest risk of developing CRC followed in frequency by endometrial carcinoma. Patients are also at increased risk of cancers of the stomach, ovary, urinary tract, small intestine, and prostate [11] . The estimated cumulative risk of CRC by age 70 years for LS patients was approximately 50 % in case of MLH1 or MSH2 mutations [12] (Fig. 1 ). & CRCs from LS patients are significantly less likely to carry KRAS mutations compared to pMMR/MSS cancers, and importantly, BRAF V600E mutations are lacking in these patients. Among dMMR/MSI CRCs, BRAF V600E mutation testing can be performed to distinguish LS cases from sporadic dMMR tumors [13] (Fig. 1 [17, 18] . CIMP represents dense promoter hypermethylation of cancer-specific genes. CIMP-related silencing of the MLH1 gene is responsible for about 80 % of cases in which MLH1/PMS2 protein expression are lost [7] . & Approximately 50 % of sporadic dMMR cases harbor BRAF (V600E) mutations [19, 20] that indicate a sporadic origin and thereby distinguish them from LS cases [13] . & Patients with MSI-H sporadic CRCs share most of the clinicopathological features with LS cases, yet have distinct epidemiological features including older age at diagnosis, predominance of female gender, and increased rate of cigarette smoking [21] . 
Phenotypic features of deficient MMR CRCs

5-FU plus oxaliplatin adjuvant therapy
& In stage III colon cancer patients, oxaliplatin combined with 5-FU is the current standard of care for adjuvant chemotherapy [45] [46] [47] . & In contrast to 5-FU, sensitivity to oxaliplatin was independent of the MMR system in CRC cell lines [48] . 
